RecruitingNot applicableNCT06055179
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
Studying Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
- Principal Investigator
- Haibo Zhang, Prof.Guangdong Provincial Hospital of Traditional Chinese Medicine
- Intervention
- Xiao Chai Hu Tang (XCHT)(drug)
- Enrollment
- 98 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
Collaborators
University of Houston
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06055179 on ClinicalTrials.gov